Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
1. Novo Nordisk's net profit exceeded analyst expectations at $4.4 billion. 2. Wegovy sales fell short of forecasts, affecting future growth outlook. 3. Company lowers 2025 sales growth forecast to 13%-21%, below prior projections. 4. Increasing competition in weight-loss drugs dampens market sentiment for Novo. 5. Eli Lilly's sales growth highlights competitive pressure in the obesity drug market.